fda halts glp-1 Compounders protest as removes tirzepatide off shortage list FDA Halts Sale of Off-Brand

Han, Y., Li, Y

The Accessibility Challenge in Weight Loss Treatment For years, individuals struggling with obesity have faced multiple obstacles in accessing medical-grade weight loss solutions: Prohibitive costs: Branded GLP-1 medications can exceed $1,000-$1,300 monthly without insurance coverage Insurance hurdles: Many plans exclude weight loss medications or require extensive prior authorization processes Limited provider access: Specialists may have months-long waitlists Geographic barriers: Quality weight management clinics may not exist in rural or underserved areas Time constraints: Traditional appointments require time off work and commuting Telehealth platforms like Freya Meds address these challenges by leveraging technology, compounded medications, and direct-to-consumer models that prioritize convenience and transparency

S., Bremmer, M

Intimately familiar with the amino acid structure of glucagon, Mojsov had a hunch that the active part of GLP-1 might in fact be located in a small stretch of the peptide

Semaglutide represents the most widely discussed GLP-1 receptor agonist for weight management